Two mRNA vaccines against COVID-19 have proven safe and effective in clinical trials, as well as in the millions of people who have been vaccinated so far. But how prior SARS-CoV-2 infection affects vaccine response, and how long that response lasts, are still uncertain. Now, a new study in ACS Nano supports increasing evidence that people who had COVID-19 need only one vaccine dose, and that boosters could be necessary for everyone in the future.
Vivid photos of the red 'COVID arm' rash and reports of facial swelling in patients who have received dermatological fillers after Pfizer-BioNTech or Moderna vaccination for COVID-19 may increase patients' concerns about mRNA vaccine side effects and contribute to vaccine hesitancy. A comprehensive review in Clinics in Dermatology, conducted by University of Connecticut School of Medicine researchers and published by Elsevier, confirms that almost all cutaneous reactions are largely self-limited and should not discourage getting the vaccine.
The rapid development of safe and efficacious vaccines against SARS-CoV-2 has offered hope that the global COVID-19 pandemic may soon be under control.
A project led by Dr. Sophia Newcomer in the University of Montana's Center for Population Health Research is the first spatial scan analysis to identify hotspots of undervaccinated children across Montana and evaluate whether they are due to social or geographic barriers.
The largest, most extensive global study of background rates for adverse events of special interest identifies important differences by age, sex, and database that will inform COVID vaccine safety monitoring.
In two separate articles in the Annals of Neurology, clinicians in India and England report cases of a rare neurological disorder called Guillain-Barre? syndrome after individuals were vaccinated against COVID-19.
All coronaviruses produce four primary structural proteins and multiple nonstructural proteins. However, the majority of antibody-based SARS-CoV-2 research has focused on the spike and nucleocapsid proteins. A study published in PLOS Biology by Anna Heffron, Irene Ong and colleagues at the University of Wisconsin-Madison, USA, suggests that immune responses may develop against other proteins produced by the SARS-CoV-2 virus.
In a study published in the journal Cell, Duke investigators demonstrated in mice and monkeys that human antibodies lacked the ability to make SARS-CoV-2 infection worse and, instead, exerted their defensive powers against the infection. The findings help reinforce evidence that antibodies are safe when given as treatments or induced by COVID-19 vaccines.
In joint research, POSTECH professor Inhwan Hwang develops a new avian influenza vaccine using plant-based recombinant protein.
People who struggle with social anxiety might experience increased distress related to mask-wearing during and even after the COVID-19 pandemic.